B Cell Lymphoma
Conference Coverage
On second thought, lenalidomide does improve DLBCL outcomes
LUGANO, SWITZERLAND – Adding lenalidomide to R-CHOP reduced the risk of diffuse large B-cell lymphoma progression or death by 34% in the ECOG-...
Conference Coverage
Acalabrutinib extends PFS in advanced CLL
AMSTERDAM – Monotherapy with the Bruton tyrosine kinase inhibitor acalabrutinib offered better progression-free survival, compared with rituximab-...
Conference Coverage
Ibrutinib tops chlorambucil against CLL
AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.
Conference Coverage
R2-CHOP doesn’t improve survival in DLBCL
LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...
From the Journals
CNS-directed therapy appears more effective for synDLBCL
Two-year survival rates were superior among patients who received CNS-intensive therapy.
Conference Coverage
No benefit with rituximab after first CR in DLBCL
AMSTERDAM – Rituximab maintenance was no better than observation for patients in first complete remission after induction chemotherapy with R-CHOP...
From the Journals
Radiation bridging with axi-cel appears safe in DLBCL
At final follow-up, in a case series of 12 patients with relapsed/refractory DLBCL, the best objective response rate was 81.8%, with complete...
From the Journals
Polatuzumab vedotin combo shows promise in DLBCL
Polatuzumab vedotin plus rituximab or obinutuzumab, in addition to cyclophosphamide, doxorubicin, and prednisone, showed manageable safety and...
From the Journals
Influenza vaccination status in DLBCL poorly documented
Routine outpatient vaccination screening and strategies for sharing and linking patient vaccination status could improve vaccination documentation...
Conference Coverage
Rituximab and vemurafenib could challenge frontline chemotherapy for HCL
AMSTERDAM – The investigators called for randomized testing to compare the combination to standard chemotherapy in the frontline setting for hairy...
Conference Coverage
Cell count ratios appear to predict thromboembolism in lymphoma
AMSTERDAM – The findings mean clinicians can look to complete blood count for answers on thromboembolism risk.